贝伐珠单抗联合厄洛替尼一线治疗EGFR突变晚期非鳞非小细胞肺癌:BEVERLY多中心随机3期试验
BEVERLY是一项意大利多中心随机3期试验,将160例EGFR突变晚期非鳞NSCLC患者按1:1随机分配至厄洛替尼联合贝伐珠单抗组或厄洛替尼单药组。中位随访36.3个月时,研究者评估的中位无进展生存期(PFS)联合组为15.4个月(95%CI:12.2-18.6),单药组为9.6个月(95%CI:8.2-10.6),风险比=0.66(95%CI:0.47-0.92),盲法独立中心审查的PFS分析证实该结果。联合组高血压、皮疹、血栓栓塞事件和蛋白尿的发生率均高于单药组,但未出现非预期安全性问题。
要点
- 联合组研究者评估的中位PFS为15.4个月,单药组为9.6个月,风险比=0.66。
- 吸烟习惯与治疗效应存在统计学显著交互作用(p=0.0323),PFS延长仅在当前或既往吸烟者中具有临床意义。
- 联合组3级及以上高血压(24% vs 5%)、3级及以上皮疹(31% vs 14%)、任何级别血栓栓塞事件(11% vs 4%)和任何级别蛋白尿(23% vs 6%)均较单药组更常见。
核心结论
- 在意大利EGFR突变晚期NSCLC患者中,厄洛替尼联合贝伐珠单抗一线治疗较厄洛替尼单药延长了PFS。
- 联合治疗毒性增加,但未出现非预期安全性问题。
研究设计与样本
- BEVERLY是一项意大利多中心、随机、3期试验(NCT02633189;EudraCT 2015-002235-17)。
- 2016年4月11日至2019年2月27日期间,共160例患者按1:1随机分配至厄洛替尼联合贝伐珠单抗组(80例)或厄洛替尼单药组(80例)。
- 共同主要终点为研究者评估的PFS和盲法独立中心审查的PFS;按检测0.60风险比、双侧α误差0.05、80%把握度计算,需160例患者中出现126个事件。
主要发现
- 中位随访36.3个月时,研究者评估的中位PFS联合组为15.4个月(95%CI:12.2-18.6),单药组为9.6个月(95%CI:8.2-10.6),风险比=0.66(95%CI:0.47-0.92)。
- 盲法独立中心审查的PFS分析证实了上述结果。
- 吸烟习惯与治疗效应存在统计学显著交互作用(p=0.0323),PFS延长仅在当前或既往吸烟者中具有临床意义。
- 3级及以上高血压发生率联合组为24%,单药组为5%;3级及以上皮疹联合组为31%,单药组为14%。
- 任何级别血栓栓塞事件发生率联合组为11%,单药组为4%;任何级别蛋白尿联合组为23%,单药组为6%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available in non-Asian patients. BEVERLY is an Italian, multicenter, randomized, phase 3 investigating the addition of bevacizumab to erlotinib as first-line treatment of advanced EGFR-mutated NSCLC. METHODS: Eligible patients were randomized 1:1 to erlotinib plus bevacizumab or erlotinib alone. Investigator-assessed PFS and blinded independent centrally reviewed PFS were coprimary end points. With 80% power in detecting a 0.60 hazard ratio and two-sided α error of 0.05, 126 events of 160 patients were needed. The trial was registered as NCT02633189 and EudraCT 2015-002235-17. RESULTS: From April 11, 2016, to February 27, 2019, a total of 160 patients were randomized to erlotinib plus bevacizumab (80) or erlotinib alone (80). At a median follow-up of 36.3 months, median investigator-assessed PFS was 15.4 months (95% confidence interval [CI]: 12.2-18.6) with erlotinib plus bevacizumab and 9.6 months (95% CI: 8.2-10.6) with erlotinib alone (hazard ratio = 0.66, 95% CI: 0.47-0.92). Blinded independent centrally reviewed PFS analysis confirmed this result. A statistically significant interaction with treatment effect was found for smoking habit (p = 0.0323), with PFS prolongation being clinically significant only among current or previous smokers. Hypertension (grade ≥3: 24% versus 5%), skin rash (grade ≥ 3: 31% versus 14%), thromboembolic events (any grade: 11% versus 4%), and proteinuria (any grade: 23% versus 6%) were more frequent with the combination. CONCLUSIONS: The addition of bevacizumab to first-line erlotinib prolonged PFS in Italian patients with EGFR-mutated NSCLC; toxicity was increased with the combination but without unexpected safety issues.
引用
- Piccirillo MC, Bonanno L, Garassino MC, et al. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022. PMID: 35659580. doi:10.1016/j.jtho.2022.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。